Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Pentheroudakis

Showing results (41-50 of 93) with videos related to

Pageof 10
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
ESMO-Magnitude of Clinical Benefit Scale version 1.1N I Cherny, U Dafni, J Bogaerts, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies: a comprehensive review (2018-2022)J W G Derksen, D Martins-Branco, A Valachis, et al.
Oral Oncology|February 28, 2012
Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynxG Pentheroudakis, I Nicolaou, V Kotoula, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2020
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensusG Curigliano, S Banerjee, A Cervantes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2010
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG)P A Kosmidis, G Fountzilas, A G Eleftheraki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2022
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) creditS F Oosting, J Barriuso, A Bottomley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2022
Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trialsJ L Perez-Gracia, N Penel, E Calvo, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotypingJ Sgouros, A Eliades, K Papadopoulou, et al.
ESMO Open|March 4, 2023
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicinesG Zarkavelis, A L Amylidi, C Verbaanderd, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumoursA Pellat, T Grinda, P Cresta Morgado, et al.
Pageof 10

Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
ESMO-Magnitude of Clinical Benefit Scale version 1.1N I Cherny, U Dafni, J Bogaerts, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies: a comprehensive review (2018-2022)J W G Derksen, D Martins-Branco, A Valachis, et al.
Oral Oncology|February 28, 2012
Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynxG Pentheroudakis, I Nicolaou, V Kotoula, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2020
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensusG Curigliano, S Banerjee, A Cervantes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2010
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG)P A Kosmidis, G Fountzilas, A G Eleftheraki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2022
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) creditS F Oosting, J Barriuso, A Bottomley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2022
Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trialsJ L Perez-Gracia, N Penel, E Calvo, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotypingJ Sgouros, A Eliades, K Papadopoulou, et al.
ESMO Open|March 4, 2023
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicinesG Zarkavelis, A L Amylidi, C Verbaanderd, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumoursA Pellat, T Grinda, P Cresta Morgado, et al.
Pageof 10